SIGA TECHNOLOGIES INC Logo

SIGA TECHNOLOGIES INC

Develops antiviral drugs for global health security against biothreats and infectious diseases.

SIGA | US

Overview

Corporate Details

ISIN(s):
US8269171067
LEI:
Country:
United States of America
Address:
31 EAST 62ND STREET, 10065 NEW YORK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on global health security. The company develops and commercializes solutions for serious infectious diseases, biothreats, and other unmet medical needs. Its lead product is TPOXX® (tecovirimat), an oral antiviral drug developed to treat smallpox and other related viruses. SIGA's primary mission is to provide countermeasures against emerging infectious diseases and potential biological weapons, contributing to public health and safety.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all SIGA TECHNOLOGIES INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SIGA TECHNOLOGIES INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SIGA TECHNOLOGIES INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Greenwich LifeSciences, Inc. Logo
Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.
United States of America
GLSI
GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America
GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain
GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia
GRD1R
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America
GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America
GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden
GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea
036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America
GYRE
Haleon PLC Logo
A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.
United Kingdom
HLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.